StreetInsider.com News Articles

ZyVersa Therapeutics (ZVSA) Misses Q1 EPS by 22c

Wed, 13 May 2026 17:39:12 -0400

ZyVersa Therapeutics (NASDAQ: ZVSA) reported Q1 EPS of ($0.22).

For earnings history and earnings-related data on ZyVersa Therapeutics (ZVSA) click here.

Form 10-Q ZyVersa Therapeutics, For: Mar 31

Wed, 13 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260513/26487047.html

Form 10-Q ZyVersa Therapeutics, For: Mar 31

Wed, 13 May 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260513/26487047.html

Form 10-K ZyVersa Therapeutics, For: Dec 31

Tue, 31 Mar 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260331/26252126.html

Form 10-K ZyVersa Therapeutics, For: Dec 31

Tue, 31 Mar 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260331/26252126.html

Form 8-K ZyVersa Therapeutics, For: Feb 27

Thu, 05 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260305/26118840.html

Form 8-K ZyVersa Therapeutics, For: Feb 27

Thu, 05 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260305/26118840.html

Form 8-K ZyVersa Therapeutics, For: Dec 02

Wed, 03 Dec 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20251203/25695656.html

Form 8-K ZyVersa Therapeutics, For: Nov 19

Wed, 19 Nov 2025 16:26:00 -0400

si-local-file:///var/storage/secattach/20251119/25638632.html

Form 10-Q ZyVersa Therapeutics, For: Sep 30

Wed, 19 Nov 2025 16:16:00 -0400

si-local-file:///var/storage/secattach/20251119/25638488.html

Form NT 10-Q ZyVersa Therapeutics, For: Sep 30

Fri, 14 Nov 2025 17:01:00 -0400

si-local-file:///var/storage/secattach/20251114/25619050.html

Form 8-K ZyVersa Therapeutics, For: Oct 10

Wed, 15 Oct 2025 16:30:00 -0400

si-local-file:///var/storage/secattach/20251015/25461040.html

Form 25-NSE ZyVersa Therapeutics, Filed by: Nasdaq Stock Market LLC

Mon, 06 Oct 2025 14:19:00 -0400

si-local-file:///var/storage/secattach/20251006/25424032.html

Form 8-K ZyVersa Therapeutics, For: Sep 14

Thu, 18 Sep 2025 07:01:00 -0400

si-local-file:///var/storage/secattach/20250918/25348403.html

Form SCHEDULE 13G/A ZyVersa Therapeutics, Filed by: ARMISTICE CAPITAL, LLC

Thu, 14 Aug 2025 21:26:00 -0400

si-local-file:///var/storage/secattach/20250814/25209721.html

ZyVersa begins phase 2a trial for diabetic kidney disease treatment

Thu, 14 Aug 2025 07:55:24 -0400

ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) has initiated a phase 2a clinical trial for VAR 200, its experimental treatment for diabetic kidney disease. The company announced that patient screening is actively underway, with the first patient expected to begin therapy by the end of the current quarter.

The Weston, Florida-based biopharmaceutical company is developing VAR 200 as a Cholesterol Efflux Mediator designed to remove excess lipids from kidney cells. According to the company, the drug works by directly removing cholesterol and lipids from kidney cells while upregulating cholesterol transporters ABCA1 and ABCG1.

ZyVersa cited research published in Frontiers in Immunology that reviewed 172

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

Thu, 14 Aug 2025 07:55:00 -0400

Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.
Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstrate that fatty kidney is an independent risk factor for chronic kidney disease (CKD), not just DKD, and reinforce that lipid accumulation promotes release of pro-inflammatory cytokines leading to inflammation, fibrosis, and CKD progression.
ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess lipids from the kidneys’ filtration system. VAR 200 directly removes cholesterol and lipids from kidney cells,

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

Thu, 14 Aug 2025 07:55:00 -0400

Data show that diabetes-associated metabolic issues lead to kidney lipid accumulation, resulting in inflammation and fibrosis that cause progressive kidney damage and disease progression.
Earlier data by Kanbay et al (Eur J Clin Invest. 2022) demonstrate that fatty kidney is an independent risk factor for chronic kidney disease (CKD), not just DKD, and reinforce that lipid accumulation promotes release of pro-inflammatory cytokines leading to inflammation, fibrosis, and CKD progression.
ZyVersa is developing Cholesterol Efflux Mediator™ VAR 200 to mediate removal of damaging excess lipids from the kidneys’ filtration system. VAR 200 directly removes cholesterol and lipids from kidney cells,

ZyVersa Therapeutics (ZVSA) Misses Q2 EPS by 46c

Wed, 13 Aug 2025 18:46:50 -0400

ZyVersa Therapeutics (NASDAQ: ZVSA) reported Q2 EPS of ($0.46).

For earnings history and earnings-related data on ZyVersa Therapeutics (ZVSA) click here.

Form 10-Q ZyVersa Therapeutics, For: Jun 30

Wed, 13 Aug 2025 08:56:00 -0400

si-local-file:///var/storage/secattach/20250813/25192884.html

Form EFFECT ZyVersa Therapeutics,

Thu, 07 Aug 2025 06:06:00 -0400

si-local-file:///var/storage/secattach/20250807/25161909.html

Form S-1/A ZyVersa Therapeutics,

Fri, 01 Aug 2025 17:27:00 -0400

si-local-file:///var/storage/secattach/20250801/25137809.html

Form 8-K ZyVersa Therapeutics, For: Jul 25

Mon, 28 Jul 2025 07:56:00 -0400

si-local-file:///var/storage/secattach/20250728/25102947.html

ZyVersa raises $12 million, begins trading on OTC markets

Mon, 21 Jul 2025 07:55:32 -0400

ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) completed two financing transactions in the second quarter totaling $12 million and moved its stock listing to the OTC markets, according to a shareholder letter from Chief Executive Officer Stephen Glover.

The clinical-stage biopharmaceutical company closed a $2 million warrant inducement transaction on July 8 and a share purchase agreement for up to $10 million with Williamsburg Venture Holdings on June 25. The company began trading on the OTC markets on July 17 under the same ticker symbol ZVSA.

ZyVersa initiated a Phase 2a trial in mid-June for its lead drug candidate VAR 200 in patients with

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

Mon, 21 Jul 2025 07:55:00 -0400

WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a mid-year Shareholder Letter to update investors on recent corporate developments and to highlight near-term value-building R&D milestones for second half of 2025. The full text of the letter follows.

A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER

Dear Shareholders:

Over my 40-year career, I’ve